SCHEMBL2492937

SCHEMBL2492937

C1=Cc2oc3ccccc3c2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.40
ALDH1A1 P00352 6/20 0.40
HPGD P15428 4/20 0.40
MAPT P10636 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CYP3A4 P08684 2/20 0.40
GLA P06280 1/20 0.40
PGAM1 P18669 1/20 0.40
MAOA P21397 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TAAR1 Q96RJ0 1/20 0.37
KMT2A Q03164 5/20 0.34
MEN1 O00255 4/20 0.34
AHR P35869 2/20 0.34
NQO1 P15559 2/20 0.34
GAA P10253 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4429087 0.82 CYP2D6 (0.42) ALDH1A1SMN1; SMN2MAOATAAR1KMT2A
SCHEMBL450881 0.80 KDM4E (0.38) KDM4EALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL9383291 0.80 KDM4E (0.42) KDM4EALDH1A1HPGDMAPTHSD17B10
SCHEMBL19752534 0.78 TAAR1 (0.35) KDM4EALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL23287877 0.74 CYP2B6 (0.31) TDP1L3MBTL1
SCHEMBL30670233 0.73 KDM4E (0.44) KDM4EALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL4711831 0.73 TDP1 (0.49) KDM4EALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL4619985 0.73 KDM4E (0.44) KDM4EALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL271403 0.73 KDM4E (0.44) KDM4EALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL2243434 0.73 KDM4E (0.35) KDM4EALDH1A1HPGDMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114805268-B Synthesis method of visible light mediated cyclopenta [ b ] benzofuran derivative 河南大学 2024-03-08 CN claimed
CN-114805268-A Synthesis method of visible light mediated cyclopenta [ b ] benzofuran derivative 河南大学 2022-07-29 CN claimed
EP-1303520-A4 THERAPEUTIC COMPOUNDS AND METHODS GOVERNMENT OF THE STATE OF SAR (MY) 2005-03-30 EP claimed
EP-1303520-A1 THERAPEUTIC COMPOUNDS AND METHODS The Government of the State of Sarawak, Malaysia (MY) 2003-04-23 EP claimed
WO-2002002566-A1 THERAPEUTIC COMPOUNDS AND METHODS THE GOVERNMENT OF THE STATE OF SARAWAK, MALAYSIA (MY) 2002-01-10 WO claimed
EP-0463162-A1 PREPARATION OF 5,6,7-TRINOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES TORAY INDUSTRIES, INC. (JP) 1992-01-02 EP claimed
JP-2200652-A None JP disclosed
US-20260146034-A1 1H-CYCLOPENTA[B]BENZOFURAN DERIVATIVES FOR THE PREVENTION AND TREATMENT OF VIRUS DISEASES SJP BIOTEC GMBH (CH) 2026-05-28 US disclosed
US-20260146034-A1 1H-CYCLOPENTA[B]BENZOFURAN DERIVATIVES FOR THE PREVENTION AND TREATMENT OF VIRUS DISEASES SJP BIOTEC GMBH (CH) 2026-05-28 US disclosed
US-20260146034-A1 1H-CYCLOPENTA[B]BENZOFURAN DERIVATIVES FOR THE PREVENTION AND TREATMENT OF VIRUS DISEASES SJP BIOTEC GMBH (CH) 2026-05-28 US disclosed
US-12612395-B2 Rocaglate derivatives and uses thereof TRUSTEES OF BOSTON UNIVERSITY (US) 2026-04-28 US disclosed
EP-4687879-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF VIRAL DISEASES SJP Biotec GmbH (CH) 2026-02-11 EP disclosed
EP-4687879-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF VIRAL DISEASES SJP Biotec GmbH (CH) 2026-02-11 EP disclosed
EP-0232776-A2 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives TORAY INDUSTRIES, INC. (JP) 1987-08-19 EP disclosed
EP-0084856-B1 5,6,7-TRINOR-4, 8-INTER-M-PHENYLENE PROSTAGLANDIN I2 DERIVATIVES TORAY INDUSTRIES, INC. (JP) 1986-11-20 EP disclosed
US-4564620-A 5,6,7,-Trinor-4,8-inter-m-phenylene PGI2 derivatives and anti-ulcer, anti-thrombotic and anti-hypertensive pharmaceutical compositions containing them TORAY INDUSTRIES, INC. (JP) 1986-01-14 US disclosed
US-4539414-A ANTILEUKEMIA AGENTS MING LU KING (TW) 1985-09-03 US disclosed
US-4539414-A ANTILEUKEMIA AGENTS MING LU KING (TW) 1985-09-03 US disclosed
US-4474802-A 5,6,7-Trinor-4,8-inter-m-phenylene prostaglandin I2 derivatives useful in anti-ulcer, hypotensive and platelet aggregation inhibiting compositions TORAY INDUSTRIES, INC. (JP) 1984-10-02 US disclosed
EP-0084856-A1 5,6,7-Trinor-4, 8-inter-m-phenylene prostaglandin I2 derivatives TORAY INDUSTRIES, INC. (JP) 1983-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612395-B2 Rocaglate derivatives and uses thereof GLRB, SRR, HCAR3 KDM4E 3241/4885ALDH1A1 715/4885HPGD 1791/4885
US-20260146034-A1 1H-CYCLOPENTA[B]BENZOFURAN DERIVATIVES FOR THE PREVENTION AND TREATMENT OF VIRUS DISEASES NSUN2, NSUN3, ZC3HAV1 KDM4E 3666/4885ALDH1A1 1304/4885HPGD 4730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.